426 related articles for article (PubMed ID: 17308859)
1. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.
Reinders MK; van Roon EN; Houtman PM; Brouwers JR; Jansen TL
Clin Rheumatol; 2007 Sep; 26(9):1459-65. PubMed ID: 17308859
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
[TBL] [Abstract][Full Text] [Related]
3. Uricosuric medications for chronic gout.
Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
Cochrane Database Syst Rev; 2014 Nov; (11):CD010457. PubMed ID: 25392987
[TBL] [Abstract][Full Text] [Related]
4. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
[TBL] [Abstract][Full Text] [Related]
5. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?
Lee MH; Graham GG; Williams KM; Day RO
Drug Saf; 2008; 31(8):643-65. PubMed ID: 18636784
[TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand.
Stamp LK; Haslett J; Frampton C; White D; Gardner D; Stebbings S; Taylor G; Grainger R; Kumar R; Kumar S; Kain T; Porter D; Corkill M; Cathro A; Metcalfe S; Wyeth J; Dalbeth N
Intern Med J; 2016 Sep; 46(9):1075-80. PubMed ID: 27391386
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
Perez-Ruiz F; Alonso-Ruiz A; Calabozo M; Herrero-Beites A; García-Erauskin G; Ruiz-Lucea E
Ann Rheum Dis; 1998 Sep; 57(9):545-9. PubMed ID: 9849314
[TBL] [Abstract][Full Text] [Related]
8. [Hyperuricemia and gout--treatment].
Gröbner W; Walter-Sack I
Dtsch Med Wochenschr; 2002 Feb; 127(5):210-3. PubMed ID: 11821994
[No Abstract] [Full Text] [Related]
9. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
Chou HW; Chiu HT; Tsai CW; Ting IW; Yeh HC; Huang HC; Kuo CC;
Nephrol Dial Transplant; 2018 Sep; 33(9):1620-1627. PubMed ID: 29165620
[TBL] [Abstract][Full Text] [Related]
10. Effect of Uric Acid Lowering on Renin-Angiotensin-System Activation and Ambulatory BP: A Randomized Controlled Trial.
McMullan CJ; Borgi L; Fisher N; Curhan G; Forman J
Clin J Am Soc Nephrol; 2017 May; 12(5):807-816. PubMed ID: 28320765
[TBL] [Abstract][Full Text] [Related]
11. Major unanswered questions in the clinical gout field.
Stamp LK
Curr Opin Rheumatol; 2017 Mar; 29(2):171-177. PubMed ID: 27926541
[TBL] [Abstract][Full Text] [Related]
12. Gout due to xanthine derivatives.
Toda K; Goriki K; Ochiai M; Tokunou H; Uehara S; Takahashi H; Okusaki K
Br J Rheumatol; 1997 Oct; 36(10):1131-2. PubMed ID: 9374937
[No Abstract] [Full Text] [Related]
13. Influence of urate-lowering therapies on renal handling of uric acid.
Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
[TBL] [Abstract][Full Text] [Related]
14. Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews.
Kydd AS; Seth R; Buchbinder R; Falzon L; Edwards CJ; van der Heijde DM; Bombardier C
J Rheumatol Suppl; 2014 Sep; 92():33-41. PubMed ID: 25180126
[TBL] [Abstract][Full Text] [Related]
15. Benzbromarone therapy in hyperuricaemia; comparison with allopurinol and probenecid.
Schepers GW
J Int Med Res; 1981; 9(6):511-5. PubMed ID: 7033016
[TBL] [Abstract][Full Text] [Related]
16. Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient.
Fam AG
Curr Rheumatol Rep; 2001 Feb; 3(1):29-35. PubMed ID: 11177768
[TBL] [Abstract][Full Text] [Related]
17. Drug treatment of gout.
Kelley WN; Wyngaarden JB
Semin Drug Treat; 1971 Sep; 1(2):119-47. PubMed ID: 4949305
[No Abstract] [Full Text] [Related]
18. Effect of allopurinol and benzbromarone on the concentration of uridine in plasma.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Yamakita J; Higashino K
Metabolism; 1997 Dec; 46(12):1473-6. PubMed ID: 9439546
[TBL] [Abstract][Full Text] [Related]
19. [Isolated or combined drug therapy of hyperuricemia?].
Mertz DP
Dtsch Med Wochenschr; 1977 Jul; 102(30):1096-7. PubMed ID: 891391
[No Abstract] [Full Text] [Related]
20. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
Akkasilpa S; Osiri M; Deesomchok U; Avihingsanon Y
J Med Assoc Thai; 2004 Sep; 87(9):1087-91. PubMed ID: 15516011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
